<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Dev Immunol</journal-id><journal-id journal-id-type="publisher-id">CDI</journal-id><journal-title>Clinical and Developmental Immunology</journal-title><issn pub-type="ppub">1740-2522</issn><issn pub-type="epub">1740-2530</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2007/52040</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Soluble Triggering Receptor Expressed on Myeloid Cells 1 Is Released in Patients with Stable Chronic Obstructive Pulmonary Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Radsak</surname><given-names>Markus P.</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2</sup></xref><xref ref-type="aff" rid="I2"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Taube</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Haselmayer</surname><given-names>Philipp</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tenzer</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Salih</surname><given-names>Helmut R.</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wiewrodt</surname><given-names>Rainer</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Buhl</surname><given-names>Roland</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Schild</surname><given-names>Hansj&#x000f6;rg</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Institute of Immunology, University of Mainz, Obere Zahlbacher Street 67, 55131 Mainz, Germany</aff><aff id="I2"><sup>2</sup>III Medical Clinic, University of Mainz, Langenbeck Street 1, 55101 Mainz, Germany</aff><aff id="I3"><sup>3</sup>University Medical Hospital, Department of Medicine II, University of T&#x000fc;bingen,Otfried-M&#x000fc;ller-Street 10, 72076 T&#x000fc;bingen, Germany</aff><author-notes><corresp id="cor1">*Markus P. Radsak: <email>radsak@uni-mainz.de</email></corresp><fn fn-type="other"><p>Recommended by Kurt Blaser</p></fn></author-notes><pub-date pub-type="ppub"><year>2007</year></pub-date><pub-date pub-type="epub"><day>5</day><month>11</month><year>2007</year></pub-date><volume>2007</volume><elocation-id>52040</elocation-id><history><date date-type="received"><day>13</day><month>6</month><year>2007</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Markus P. Radsak et al.</copyright-statement><copyright-year>2007</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Chronic obstructive pulmonary disease (COPD) is increasingly recognized as a systemic disease that is associated with increased serum levels of markers of systemic inflammation. The triggering receptor expressed on myeloid cells 1 (TREM-1) is a recently identified activating receptor on neutrophils, monocytes, and macrophage subsets. TREM-1 expression is upregulated by microbial products such as the toll-like receptor ligand lipoteichoic acid of Gram-positive or lipopolysaccharides of Gram-negative bacteria. In the present study, sera from 12 COPD patients (GOLD stages I&#x02013;IV, <inline-formula><mml:math id="M1"><mml:mrow><mml:msub><mml:mrow><mml:mtext>FEV</mml:mtext></mml:mrow><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> 51 <inline-formula><mml:math id="M2"><mml:mrow><mml:mo>&#x000b1;</mml:mo></mml:mrow></mml:math></inline-formula> 6%) and 10 healthy individuals were retrospectively analyzed for soluble TREM-1 (sTREM-1) using a newly developed ELISA. In healthy subjects, sTREM-1 levels were low (median 0.25 ng/mL, range 0&#x02013;5.9 ng/mL). In contrast, levels of sTREM-1 in sera of COPD patients were significantly increased (median 11.68 ng/mL, range 6.2&#x02013;41.9 ng/mL, <inline-formula><mml:math id="M3"><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:math></inline-formula>). Furthermore, serum levels of sTREM-1 showed a significant negative correlation with lung function impairment. In summary, serum concentrations of sTREM-1 are increased in patients with COPD. Prospective studies are warranted to evaluate the relevance of sTREM-1 as a potential marker of the disease in patients with COPD.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Chronic obstructive pulmonary disease (COPD) is characterized by progressive development for the most part irreversible airflow obstruction that involves an abnormal airway inflammatory response [<xref ref-type="bibr" rid="B1">1</xref>]. The clinical course of COPD is typically dominated by intermittent exacerbations, responsible for the majority of the disease-associated morbidity and mortality [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>].</p><p>In recent years COPD has more and more been characterized as a systemic inflammatory disease. Several mediators have been found increased in blood of COPD patients indicating persistent systemic inflammation [<xref ref-type="bibr" rid="B4">4</xref>]. The origin of this inflammatory response is unknown but several different mechanisms including smoking itself, a cytokine &#x0201c;spill over&#x0201d; from the lungs, tissue hypoxia, and genetic factors [<xref ref-type="bibr" rid="B5">5</xref>] or persistent bacterial colonization of the airways [<xref ref-type="bibr" rid="B6">6</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>] have been suggested.</p><p>The triggering receptor expressed on myeloid cells (TREM-1) is a recently identified activating receptor on neutrophil granulocytes (PMN), monocytes, and macrophage subsets [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B12">12</xref>]. The expression of TREM-1 is upregulated by microbial products, that is, by toll-like receptor ligands such as lipoteichoic acid (LTA) of Gram-positive or lipopolysaccharide (LPS) of Gram-negative bacteria. Ligation of TREM-1 is synergistic with TLR agonists on the activation of receptor bearing cells for the release of inflammatory mediators like TNF-<inline-formula><mml:math id="M4"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> and IL-8 and the initiation of neutrophil respiratory burst [<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. We recently reported that a natural ligand for TREM-1 is present on platelets, although it still needs to be identified [<xref ref-type="bibr" rid="B14">14</xref>]. The biological significance of TREM-1 in acute inflammatory responses is documented in mouse models for septic shock, where competition of TREM-1 with a recombinant soluble TREM-1 fusion protein or an putative receptor blocking peptide derived from a conserved region of TREM-1 saved mice from lethal LPS challenge or bacterial sepsis [<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B17">17</xref>].</p><p>TREM-1 is also produced in a soluble form [<xref ref-type="bibr" rid="B18">18</xref>] and released in humans after endotoxin exposition [<xref ref-type="bibr" rid="B19">19</xref>] or in patients suffering from severe pneumonia [<xref ref-type="bibr" rid="B20">20</xref>] or sepsis [<xref ref-type="bibr" rid="B21">21</xref>]. In these critically ill patients, elevated levels of soluble TREM-1 (sTREM-1) are detectable in bronchoalveolar lavage (BAL) fluid or in plasma, respectively, and have a high accuracy and sensitivity in detecting microbial infections as underlying disease [<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. In addition, the time course of sTREM-1 levels might be a useful parameter in predicting the outcome in sepsis patients [<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B25">25</xref>]. However, a limitation of these studies is certainly that only critically ill patients were examined. A recent study by Richeldi et al. demonstrates that an increase in sTREM-1 is also detectable in patients suffering from community acquired pneumonia caused by extracellular bacteria, but not in patients with interstitial lung disease or tuberculosis [<xref ref-type="bibr" rid="B26">26</xref>]. Furthermore, sTREM-1 has been associated with major abdominal surgery and peptic ulcer disease [<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>].</p><p>In the present study, we developed a sensitive enzyme-linked immunosorbent assay (ELISA) that is able to detect pg/mL amounts of sTREM-1 in serum of patients. Using this new TREM-1 specific assay, we assessed the amount of sTREM-1 released in 12 patients suffering from COPD and 10 healthy individuals for sTREM-1 and indeed found elevated levels of sTREM-1 in patients COPD, which correlated with disease severity. </p></sec><sec sec-type="section" id="sec2"><title>2. PATIENTS, MATERIALS, AND METHODS</title><sec sec-type="subsection" id="subsec2.1"><title>2.1. Patients</title><p>Twelve patients with COPD, all current smokers or exsmokers, were recruited on the basis of their clinical diagnosis and lung function impairment. None of the patients had lung diseases other than COPD and all were in a stable clinical condition for at least 3 month. The control group comprised 10 healthy nonsmoking individuals without the sign of airway obstruction and other significant illness. The study was approved by the local Ethics Committee.</p><p>All patients with COPD were under treatment with inhaled <inline-formula><mml:math id="M5"><mml:mrow><mml:msub><mml:mrow><mml:mi>&#x003b2;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>-adrenoceptor agonists and/or anticholinergics, 3 patients were treated additionally with inhaled steroids, 3 with systemic steroids, and 2 with additional theophyllin, whereas the healthy control subjects did not have medication. Regarding baseline characteristics, there were no other significant differences between groups, except for lung function (<xref ref-type="table" rid="tab1">Table 1</xref>).</p></sec><sec sec-type="subsection" id="subsec2.2"><title>2.2. Assessment of lung function</title><p>Lung function measurements including the determination of forced expiratory volume in 1&#x02009;s (FEV<sub>1</sub>), forced vital capacity (FVC), residual volume (RV), intrathoracic gas volume (ITGV), and single breath diffusion capacity for carbon monoxide (DLCO) were performed following established guidelines [<xref ref-type="bibr" rid="B29">29</xref>&#x02013;<xref ref-type="bibr" rid="B31">31</xref>] using standard equipment (Masterlab, Jaeger, H&#x000f6;chberg, Germany). Bronchodilator responses were quantified as absolute and percent increase of FEV<sub>1</sub> measured 15&#x02009;minutes after inhalation of 200 <inline-formula><mml:math id="M6"><mml:mrow><mml:mi>&#x003bc;</mml:mi><mml:mtext>g</mml:mtext></mml:mrow></mml:math></inline-formula> salbutamol.</p></sec><sec sec-type="subsection" id="subsec2.3"><title>2.3. Transfectants</title><p>Full-length cDNA encoding TREM-1 cloned in the eukaryontic expression vector pcDNA3 (Invitrogen) were stably transfected in HEK293 cells with Fugene 6 (Roche) according to standard protocols. The TREM-1cDNAs have been described previously [<xref ref-type="bibr" rid="B11">11</xref>]. Transfectants were obtained after G418 selection.</p><p>The production recombinant TREM-1::IgG1 fusion protein has been described previously [<xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec sec-type="subsection" id="subsec2.4"><title>2.4. Monoclonal antibodies</title><p>TREM-1 specific monoclonal antibodies (clone 6B1) were raised by repeated immunization of BALB/c mice with a recombinant TREM-1::IgG1 fusion protein according to standard procedures. Hybridoma supernatants were first screened by ELISA against TREM-1::IgG1 and human IgG (Sigma-Aldrich, Taufkirchen), respectively. Supernatants reacting against TREM-1::IgG1, but not IgG, were subcloned twice and further screened by flow cytometry using TREM-1-transfected 293 cells. Antibodies (Abs) were purified by affinity chromatography on a protein G-Sepharose column. The mAb clones 1C5 and 6B1 were of isotype IgG1.</p></sec><sec sec-type="subsection" id="subsec2.5"><title>2.5. Detection of soluble TREM-1 by ELISA</title><p>For the detection of soluble TREM-1 (sTREM-1), anti-TREM-1 (6B1) mAb was coated at 0.5 <inline-formula><mml:math id="M7"><mml:mrow><mml:mi>&#x003bc;</mml:mi></mml:mrow></mml:math></inline-formula>g/mL in PBS, then blocked by addition of 100 <inline-formula><mml:math id="M8"><mml:mrow><mml:mi>&#x003bc;</mml:mi><mml:mtext>L</mml:mtext></mml:mrow></mml:math></inline-formula> of 15% BSA for 2 hours at <inline-formula><mml:math id="M9"><mml:mrow><mml:msup><mml:mrow><mml:mn>37</mml:mn></mml:mrow><mml:mrow><mml:mo>&#x000b0;</mml:mo></mml:mrow></mml:msup><mml:mtext>C</mml:mtext></mml:mrow></mml:math></inline-formula> and washed. Afterward the standard (recombinant TREM-1::IgG1 in 7.5% BSA-PBS) and the samples were added and the plates were incubated for 2 hours at <inline-formula><mml:math id="M10"><mml:mrow><mml:msup><mml:mrow><mml:mn>37</mml:mn></mml:mrow><mml:mrow><mml:mo>&#x000b0;</mml:mo></mml:mrow></mml:msup><mml:mtext>C</mml:mtext></mml:mrow></mml:math></inline-formula>. For analysis of patient samples, sera were diluted <inline-formula><mml:math id="M11"><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math></inline-formula> in 5% BSA prior to addition to the plates. After incubation, plates were washed and the biotinylated detection polyclonal Ab anti-TREM-1 (R&#x00026;D Systems) at 5 <inline-formula><mml:math id="M12"><mml:mrow><mml:mi>&#x003bc;</mml:mi></mml:mrow></mml:math></inline-formula>g/mL in 7.5% BSA-PBS was added for 2 hours at <inline-formula><mml:math id="M13"><mml:mrow><mml:msup><mml:mrow><mml:mn>37</mml:mn></mml:mrow><mml:mrow><mml:mo>&#x000b0;</mml:mo></mml:mrow></mml:msup><mml:mtext>C</mml:mtext></mml:mrow></mml:math></inline-formula>. Plates were then washed and streptavidine-HRP (<inline-formula><mml:math id="M14"><mml:mrow><mml:mn>1</mml:mn><mml:mo>:</mml:mo><mml:mn>8000</mml:mn></mml:mrow></mml:math></inline-formula> in 7.5% BSA-PBS) was added for 1 hour at <inline-formula><mml:math id="M15"><mml:mrow><mml:msup><mml:mrow><mml:mn>37</mml:mn></mml:mrow><mml:mrow><mml:mo>&#x000b0;</mml:mo></mml:mrow></mml:msup><mml:mtext>C</mml:mtext></mml:mrow></mml:math></inline-formula>. Plates were then washed again and developed using the Tetramethylbenzidine Peroxidase Substrate System (KPL, Gaithersburg, Md). The absorbance was measured at 450 nm. Results are shown as means with SD of triplicates. The lower detection limit was defined by 2x SD of the blank values (5 pg/mL). The recovery rate was <inline-formula><mml:math id="M16"><mml:mrow><mml:mn>90.6</mml:mn><mml:mo>+</mml:mo><mml:mo>/</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn><mml:mn>%</mml:mn></mml:mrow></mml:math></inline-formula>. Intraassay variation was <inline-formula><mml:math id="M17"><mml:mrow><mml:mn>7</mml:mn><mml:mo>+</mml:mo><mml:mo>/</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>, interassay variation was <inline-formula><mml:math id="M18"><mml:mrow><mml:mn>6</mml:mn><mml:mo>+</mml:mo><mml:mo>/</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>5</mml:mn><mml:mo>%</mml:mo></mml:mrow></mml:math></inline-formula>.</p></sec><sec sec-type="subsection" id="subsec2.6"><title>2.6. Statistical procedures</title><p>Mean values, medians, and standard deviation (SD) were computed. sTREM-1 levels were compared between groups using Mann-Whitney-U test. Lung function and other values were compared between groups using unpaired <inline-formula><mml:math id="M19"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:math></inline-formula>-test. Correlation analysis was performed by Spearman&#x02019;s rank correlation. Statistical significance was assumed for <inline-formula><mml:math id="M20"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:mrow></mml:math></inline-formula>.</p></sec></sec><sec sec-type="section" id="sec3"><title>3. RESULTS</title><sec sec-type="subsection" id="subsec3.1"><title>3.1. Detection of sTREM-1 in serum by ELISA</title><p>To evaluate the newly developed assay TREM-1-IgG recombinant human TREM-1::IgG1 and serum form a patient with sepsis were analyzed in serial dilutions since high levels of sTREM-1 have been described in sepsis previously [<xref ref-type="bibr" rid="B22">22</xref>]. As depicted in <xref ref-type="fig" rid="fig1">Figure 1</xref>, the assay allowed the detection of sTREM-1 down to 5 pg/mL sTREM-1 concluding that this new ELISA protocol is a suitable tool to investigate the significance of sTREM-1 in patients.</p></sec><sec sec-type="subsection" id="subsec3.2"><title>3.2. Serum levels of sTREM-1 are elevated in patients with COPD</title><p>None of the control patients showed airway obstruction (<xref ref-type="table" rid="tab1">Table 1</xref>), whereas COPD patients showed a significantly decreased FEV<sub>1</sub> and FEV<sub>1</sub>% predicted (<xref ref-type="table" rid="tab1">Table 1</xref>). According to GOLD criteria 2, patients were categorized as stage I (mild), 3 patients as stage II (moderate), 6 patients as stage III (severe) and 1 patients as stage IV (very severe) [<xref ref-type="bibr" rid="B33">32</xref>]. COPD patients also showed a significant increase in RV (<inline-formula><mml:math id="M21"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.015</mml:mn></mml:mrow></mml:math></inline-formula>) as well as ITGV (<inline-formula><mml:math id="M22"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.035</mml:mn></mml:mrow></mml:math></inline-formula>) and a significant decrease in DLCO (<inline-formula><mml:math id="M23"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:mrow></mml:math></inline-formula>) compared to the control subjects (<xref ref-type="table" rid="tab1">Table 1</xref>). None of the COPD patients showed a positive response to salbutamol, defined as an increase in FEV<sub>1</sub> of at least 15% and 200 mL. Serum levels of sTREM-1 were significantly (<inline-formula><mml:math id="M24"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.019</mml:mn></mml:mrow></mml:math></inline-formula>) increased in patients with COPD compared to controls. In contrast, in healthy subjects sTREM-1 was detectable in serum samples of only 6 subjects (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p></sec><sec sec-type="subsection" id="subsec3.3"><title>3.3. Relationship between serum levels of sTREM-1 and clinical parameters</title><p>Levels of sTREM-1 in serum were correlated with absolute FEV<sub>1</sub> (<inline-formula><mml:math id="M25"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.74</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M26"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.001</mml:mn></mml:mrow></mml:math></inline-formula>), FEV<sub>1</sub>% predicted (<inline-formula><mml:math id="M27"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.78</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M28"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:mrow></mml:math></inline-formula>) (<xref ref-type="fig" rid="fig3">Figure 3</xref>) and FEV<sub>1</sub>% VC (<inline-formula><mml:math id="M29"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.82</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M30"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:mrow></mml:math></inline-formula>). Also significant correlations were detected to RV (<inline-formula><mml:math id="M31"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>0.48</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M32"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.024</mml:mn></mml:mrow></mml:math></inline-formula>), DLCO (<inline-formula><mml:math id="M33"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.78</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M34"><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.001</mml:mn></mml:mrow></mml:math></inline-formula>) and VC % predicted (<inline-formula><mml:math id="M35"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.47</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M36"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.028</mml:mn></mml:mrow></mml:math></inline-formula>). No relationship was found between sTREM-1 and BMI (<inline-formula><mml:math id="M37"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.28</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M38"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.215</mml:mn></mml:mrow></mml:math></inline-formula>), age of the patient (<inline-formula><mml:math id="M39"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>0.11</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M40"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.64</mml:mn></mml:mrow></mml:math></inline-formula>), height (<inline-formula><mml:math id="M41"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.13</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M42"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.553</mml:mn></mml:mrow></mml:math></inline-formula>), or weight (<inline-formula><mml:math id="M43"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x02212;</mml:mo><mml:mn>0.39</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula><mml:math id="M44"><mml:mrow><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>.069</mml:mn></mml:mrow></mml:math></inline-formula>).</p><p>Due to the limited number of patients in our study, it was not possible to analyze correlations between lung function parameter and sTREM-1 levels.</p></sec></sec><sec sec-type="section" id="sec4"><title>4. DISCUSSION</title><p>In the present study, we show that sTREM-1 levels in serum are elevated in patients with COPD compared to healthy, nonsmoking controls. Furthermore, we demonstrate that serum levels of sTREM-1 are correlated with disease severity.</p><p>COPD is a multicomponent disease which includes inflammatory changes in the lung. Inflammatory cells in lungs of patients with COPD are mainly neutrophil granulocytes and inflammation in the lung is more pronounced with worse lung function [<xref ref-type="bibr" rid="B34">33</xref>]. Also, numbers of neutrophils in sputum correlate with disease progression [<xref ref-type="bibr" rid="B35">34</xref>]. In many patients, COPD has also significant systemic consequences. This includes loss of lean bodymass, cardiovascular effects, osteoporosis, muscle wasting but also a systemic inflammatory response. Indeed, in patients with COPD, even during stable disease, there is an increased number of leukocytes in peripheral blood [<xref ref-type="bibr" rid="B36">35</xref>, <xref ref-type="bibr" rid="B37">36</xref>] Peripheral neutrophils from patients with COPD show enhanced chemotaxis and extracellular proteolysis [<xref ref-type="bibr" rid="B38">37</xref>], produce more reactive oxygen species [<xref ref-type="bibr" rid="B39">38</xref>], and enhanced expression of several surface adhesion molecules [<xref ref-type="bibr" rid="B40">39</xref>]. Also increased levels of TNF-<inline-formula><mml:math id="M45"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula>, IL-6, IL-8, C-reactive protein, and fibrinogen in serum can be detected in serum of patients with stable COPD and some of these systemic inflammatory changes seem to be related to disease severity [<xref ref-type="bibr" rid="B4">4</xref>] and correlate with severity of systemic consequences like muscle wasting [<xref ref-type="bibr" rid="B41">40</xref>].</p><p>In the present study, we describe a new ELISA for the detection of sTREM-1 in serum. In contrast, most previous studies have used an immunodot blot technique for the detection of sTREM-1 [<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B42">41</xref>]. This technique allows the sensitive detection of sTREM-1 in body fluids. However, for assessment of sTREM-1 in a clinical routine setting detection by sandwich ELISA has the advantage that greater sample numbers may be processed simultaneously with increased specificity. Therefore, we developed a new sensitive ELISA using a monoclonal antibody to capture sTREM-1 in sera of patients and a polyclonal anti-TREM-1 for detection. Using our new sandwich-ELISA protocol, we established a standard laboratory method for the sensitive and specific detection of sTREM-1 in body fluids avoiding the pitfalls and potential disadvantages associated with the immunodot blot technique used so far. When analyzing serum samples from patients with stable COPD, we were able to detect sTREM-1 in all samples. In contrast, in samples from healthy control subjects sTREM-1 was only detectable in 6 of the patients and only in very low amounts. In line with previous data obtained from patients suffering from severe inflammatory disorders like pneumonia or sepsis [<xref ref-type="bibr" rid="B22">22</xref>&#x02013;<xref ref-type="bibr" rid="B24">24</xref>], our data indicate that sTREM-1 might be a result of neutrophil activation also in COPD patients. The current view in terms of the pathophysiology suggests that sTREM-1 is an anti-inflammatory mediator of sepsis [<xref ref-type="bibr" rid="B43">42</xref>], released as a counter regulator of TREM-1 mediated activation. Our recent results demonstrating that sTREM-1 interferes with the TREM-1/ligand interaction of neutrophil and platelets support this view [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Previous studies have described increased levels of sTREM-1 in patients with sepsis [<xref ref-type="bibr" rid="B22">22</xref>], pneumonia [<xref ref-type="bibr" rid="B20">20</xref>] but also exacerbated asthma and COPD. By using an immunoblot technique, Phua et al. found increased levels of sTREM-1 especially in patients with COPD during an Anthonisen-type 1 exacerbation [<xref ref-type="bibr" rid="B42">41</xref>]. </p><p>The authors speculated that the patients with type 1 exacerbation shad higher airway bacterial loads, which triggered systemic inflammation and increased sTREM-1 levels [<xref ref-type="bibr" rid="B45">43</xref>, <xref ref-type="bibr" rid="B46">44</xref>]. In the present study, increased levels of sTREM-1, measured by ELISA, were detected even in patients with stable disease. This could be due to an increased sensitivity of the newly introduced ELISA.</p><p>Potential explanations for the increased levels of sTREM-1 observed in this group of stable patients with COPD could be persistent bacterial colonization of the airways, which has been demonstrated by several groups [<xref ref-type="bibr" rid="B6">6</xref>&#x02013;<xref ref-type="bibr" rid="B9">9</xref>]. These colonizations can be associated with elevated levels of inflammatory mediators like IL-8, LTB4, and TNF-<inline-formula><mml:math id="M46"><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:math></inline-formula> in the lungs of patients with clinically stable disease [<xref ref-type="bibr" rid="B10">10</xref>]. In addition, increased plasma fibrinogen and IL-6 levels are detectable in these bacterially colonized patients suggesting that colonization contributes to systemic inflammation [<xref ref-type="bibr" rid="B46">44</xref>]. In patients with more advanced disease, higher levels of serum CRP have been described, suggesting increased systemic inflammatory reaction [<xref ref-type="bibr" rid="B47">45</xref>&#x02013;<xref ref-type="bibr" rid="B49">47</xref>]. As sTREM-1 can be induced by increased systemic inflammation [<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>] the increased sensitivity of our ELISA assay could be the reason for increased levels of sTREM-1 detected in the present study population.</p><p>Additionally, we found a correlation of sTREM-1 levels in serum with disease severity, described by impaired lung function, in the COPD group. This was the case when absolute and relative values of FEV<sub>1</sub> as markers for airway obstruction, RV for hyperinflation, and also diffusion capacity as a marker for emphysema were analyzed. No correlations were found for age, height, weight, or BMI. Also levels of sTREM-1 in serum were independent for medication used by patients. Some of the patients with more severe disease (GOLD stadium III&#x02013;IV) treated with systemic steroid still showed increased levels of sTREM-1 in serum. Although this analysis is somewhat limited by low numbers of patients and control sTREM-1 may yet be another systemic marker correlated with disease severity.</p><p>In summary we show increased serum levels of sTREM-1 in patients with clinical stable COPD, and a correlation between serum levels and disease severity. sTREM-1 might be a useful marker for systemic inflammation in patients with COPD. Further prospective studies are needed to evaluate the true diagnostic value of sTREM-1 in this patient population.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors thank Andrea Drescher and Annekatrin Meinl for excellent technical assistance. This work was supported by grants from the Deutsche Forschungsgemeinschaft (RA988/2-1/2 and RA988/3-1 to H. Schild and M. P. Radsak and SFB 548, A11 to C. Taube). M. P. Radsak and C. Taube contributed equally to this work.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>TF</given-names></name></person-group><article-title>The role of bacteria in airway inflammation in exacerbations of chronic obstructive pulmonary disease</article-title><source><italic>Current Opinion in Infectious Diseases</italic></source><year>2006</year><volume>19</volume><issue>3</issue><fpage>225</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">16645482</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mallia</surname><given-names>P</given-names></name><name><surname>Johnston</surname><given-names>SL</given-names></name></person-group><article-title>Mechanisms and experimental models of chronic obstructive pulmonary exacerbations</article-title><source><italic>Proceedings of the American Thoracic Society</italic></source><year>2005</year><volume>2</volume><issue>4</issue><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">16267363</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>S</given-names></name></person-group><article-title>Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease</article-title><source><italic>Seminars in Respiratory and Critical Care Medicine</italic></source><year>2005</year><volume>26</volume><issue>2</issue><fpage>192</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">16088436</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>WQ</given-names></name><name><surname>Man</surname><given-names>SFP</given-names></name><name><surname>Senthilselvan</surname><given-names>A</given-names></name><name><surname>Sin</surname><given-names>DD</given-names></name></person-group><article-title>Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis</article-title><source><italic>Thorax</italic></source><year>2004</year><volume>59</volume><issue>7</issue><fpage>574</fpage><lpage>580</lpage><pub-id pub-id-type="pmid">15223864</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agust&#x000ed;</surname><given-names>AGN</given-names></name></person-group><article-title>Systemic effects of chronic obstructive pulmonary disease</article-title><source><italic>Proceedings of the American Thoracic Society</italic></source><year>2005</year><volume>2</volume><issue>4</issue><fpage>367</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">16267364</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>AT</given-names></name><name><surname>Campbell</surname><given-names>EJ</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name><name><surname>Bayley</surname><given-names>DL</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis</article-title><source><italic>The American Journal of Medicine</italic></source><year>2000</year><volume>109</volume><issue>4</issue><fpage>288</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">10996579</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stockley</surname><given-names>RA</given-names></name><name><surname>Hill</surname><given-names>AT</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name><name><surname>Campbell</surname><given-names>EJ</given-names></name></person-group><article-title>Bronchial inflammation: its relationship to colonizing microbial load and <inline-formula><mml:math id="M47"><mml:mrow><mml:msub><mml:mi>&#x003b1;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>-antitrypsin deficiency</article-title><source><italic>Chest</italic></source><year>2000</year><volume>117</volume><issue>5, supplment 1</issue><fpage>291S</fpage><lpage>293S</lpage><pub-id pub-id-type="pmid">10843958</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soler</surname><given-names>N</given-names></name><name><surname>Ewig</surname><given-names>S</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Filella</surname><given-names>X</given-names></name><name><surname>Gonzalez</surname><given-names>J</given-names></name><name><surname>Zaubet</surname><given-names>A</given-names></name></person-group><article-title>Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease</article-title><source><italic>European Respiratory Journal</italic></source><year>1999</year><volume>14</volume><issue>5</issue><fpage>1015</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">10596683</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>S</given-names></name><name><surname>Muscarella</surname><given-names>K</given-names></name><name><surname>Evans</surname><given-names>N</given-names></name><name><surname>Klingman</surname><given-names>KL</given-names></name><name><surname>Grant</surname><given-names>BJB</given-names></name><name><surname>Murphy</surname><given-names>TF</given-names></name></person-group><article-title>Airway inflammation and etiology of acute exacerbations of chronic bronchitis</article-title><source><italic>Chest</italic></source><year>2000</year><volume>118</volume><issue>6</issue><fpage>1557</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">11115440</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>D</given-names></name><name><surname>Khair</surname><given-names>OA</given-names></name><name><surname>Honeybourne</surname><given-names>D</given-names></name></person-group><article-title>Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD</article-title><source><italic>European Respiratory Journal</italic></source><year>2004</year><volume>23</volume><issue>5</issue><fpage>685</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">15176680</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouchon</surname><given-names>A</given-names></name><name><surname>Dietrich</surname><given-names>J</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><article-title>Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes</article-title><source><italic>Journal of Immunology</italic></source><year>2000</year><volume>164</volume><issue>10</issue><fpage>4991</fpage><lpage>4995</lpage></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schenk</surname><given-names>M</given-names></name><name><surname>Bouchon</surname><given-names>A</given-names></name><name><surname>Birrer</surname><given-names>S</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>C</given-names></name></person-group><article-title>Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine</article-title><source><italic>Journal of Immunology</italic></source><year>2005</year><volume>174</volume><issue>1</issue><fpage>517</fpage><lpage>524</lpage></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Radsak</surname><given-names>MP</given-names></name><name><surname>Salih</surname><given-names>HR</given-names></name><name><surname>Rammensee</surname><given-names>H-G</given-names></name><name><surname>Schild</surname><given-names>H</given-names></name></person-group><article-title>Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival</article-title><source><italic>Journal of Immunology</italic></source><year>2004</year><volume>172</volume><issue>8</issue><fpage>4956</fpage><lpage>4963</lpage></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haselmayer</surname><given-names>P</given-names></name><name><surname>Grosse-Hovest</surname><given-names>L</given-names></name><name><surname>von Landenberg</surname><given-names>P</given-names></name><name><surname>Schild</surname><given-names>H</given-names></name><name><surname>Radsak</surname><given-names>MP</given-names></name></person-group><article-title>TREM-1 ligand expression on platelets enhances neutrophil activation</article-title><source><italic>Blood</italic></source><year>2007</year><volume>110</volume><issue>3</issue><fpage>1029</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">17452516</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouchon</surname><given-names>A</given-names></name><name><surname>Facchetti</surname><given-names>F</given-names></name><name><surname>Weigand</surname><given-names>MA</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><article-title>TREM-1 amplifies inflammation and is a crucial mediator of septic shock</article-title><source><italic>Nature</italic></source><year>2001</year><volume>410</volume><issue>6832</issue><fpage>1103</fpage><lpage>1107</lpage><pub-id pub-id-type="pmid">11323674</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>Kolopp-Sarda</surname><given-names>M-N</given-names></name><name><surname>B&#x000e9;n&#x000e9;</surname><given-names>M-C</given-names></name><etal/></person-group><article-title>A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis</article-title><source><italic>Journal of Experimental Medicine</italic></source><year>2004</year><volume>200</volume><issue>11</issue><fpage>1419</fpage><lpage>1426</lpage><pub-id pub-id-type="pmid">15557347</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>Buonsanti</surname><given-names>C</given-names></name><name><surname>Massin</surname><given-names>F</given-names></name><etal/></person-group><article-title>Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock</article-title><source><italic>Infection and Immunity</italic></source><year>2006</year><volume>74</volume><issue>5</issue><fpage>2823</fpage><lpage>2830</lpage><pub-id pub-id-type="pmid">16622220</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>M-C</given-names></name><name><surname>Lapillonne</surname><given-names>H</given-names></name><name><surname>Margolin</surname><given-names>JF</given-names></name></person-group><article-title>TREM-1, MDL-1, and DAP12 expression is associated with a mature stage of myeloid development</article-title><source><italic>Molecular Immunology</italic></source><year>2002</year><volume>38</volume><issue>11</issue><fpage>817</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">11922939</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>S</given-names></name><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>de Vos</surname><given-names>A</given-names></name><name><surname>Versteeg</surname><given-names>HH</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>van der Poll</surname><given-names>T</given-names></name></person-group><article-title>Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia</article-title><source><italic>Journal of Immunology</italic></source><year>2004</year><volume>173</volume><issue>12</issue><fpage>7131</fpage><lpage>7134</lpage></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>Cravoisy</surname><given-names>A</given-names></name><name><surname>Levy</surname><given-names>B</given-names></name><name><surname>Bene</surname><given-names>M-C</given-names></name><name><surname>Faure</surname><given-names>G</given-names></name><name><surname>Bollaert</surname><given-names>P-E</given-names></name></person-group><article-title>Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2004</year><volume>350</volume><issue>5</issue><fpage>451</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">14749453</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name></person-group><article-title>Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis</article-title><source><italic>Critical Care</italic></source><year>2005</year><volume>9</volume><issue>5</issue><fpage>485</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">16277737</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>Kolopp-Sarda</surname><given-names>M-N</given-names></name><name><surname>B&#x000e9;n&#x000e9;</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2004</year><volume>141</volume><issue>1</issue><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">15238365</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name></person-group><article-title>Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia and severe sepsis</article-title><source><italic>Seminars in Respiratory and Critical Care Medicine</italic></source><year>2006</year><volume>27</volume><issue>1</issue><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16508879</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Determann</surname><given-names>RM</given-names></name><name><surname>Millo</surname><given-names>JL</given-names></name><name><surname>Gibot</surname><given-names>S</given-names></name><etal/></person-group><article-title>Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia</article-title><source><italic>Intensive Care Medicine</italic></source><year>2005</year><volume>31</volume><issue>11</issue><fpage>1495</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">16195904</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>Cravoisy</surname><given-names>A</given-names></name><name><surname>Kolopp-Sarda</surname><given-names>M-N</given-names></name><etal/></person-group><article-title>Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis</article-title><source><italic>Critical Care Medicine</italic></source><year>2005</year><volume>33</volume><issue>4</issue><fpage>792</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">15818107</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richeldi</surname><given-names>L</given-names></name><name><surname>Mariani</surname><given-names>M</given-names></name><name><surname>Losi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections</article-title><source><italic>European Respiratory Journal</italic></source><year>2004</year><volume>24</volume><issue>2</issue><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">15332392</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koussoulas</surname><given-names>V</given-names></name><name><surname>Vassiliou</surname><given-names>S</given-names></name><name><surname>Demonakou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Soluble triggering receptor expressed on myeloid cells (sTREM-1): a new mediator involved in the pathogenesis of peptic ulcer disease</article-title><source><italic>European Journal of Gastroenterology &#x00026; Hepatology</italic></source><year>2006</year><volume>18</volume><issue>4</issue><fpage>375</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">16538108</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahdy</surname><given-names>AM</given-names></name><name><surname>Lowes</surname><given-names>DA</given-names></name><name><surname>Galley</surname><given-names>HF</given-names></name><name><surname>Bruce</surname><given-names>JE</given-names></name><name><surname>Webster</surname><given-names>NR</given-names></name></person-group><article-title>Production of soluble triggering receptor expressed on myeloid cells by lipopolysaccharide-stimulated human neutrophils involves de novo protein synthesis</article-title><source><italic>Clinical and Vaccine Immunology</italic></source><year>2006</year><volume>13</volume><issue>4</issue><fpage>492</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">16603617</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>MacIntyre</surname><given-names>N</given-names></name><name><surname>Crapo</surname><given-names>RO</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Standardisation of the single-breath determination of carbon monoxide uptake in the lung</article-title><source><italic>European Respiratory Journal</italic></source><year>2005</year><volume>26</volume><issue>4</issue><fpage>720</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">16204605</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Hankinson</surname><given-names>J</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><etal/></person-group><article-title>Standardisation of spirometry</article-title><source><italic>European Respiratory Journal</italic></source><year>2005</year><volume>26</volume><issue>2</issue><fpage>319</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">16055882</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wanger</surname><given-names>J</given-names></name><name><surname>Clausen</surname><given-names>JL</given-names></name><name><surname>Coates</surname><given-names>A</given-names></name><etal/></person-group><article-title>Standardisation of the measurement of lung volumes</article-title><source><italic>European Respiratory Journal</italic></source><year>2005</year><volume>26</volume><issue>3</issue><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">16135736</pub-id></citation></ref><ref id="B33"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>Calverley</surname><given-names>PMA</given-names></name><name><surname>Jenkins</surname><given-names>CR</given-names></name><name><surname>Hurd</surname><given-names>SS</given-names></name></person-group><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary</article-title><source><italic>American Journal of Respiratory and Critical Care Medicine</italic></source><year>2001</year><volume>163</volume><issue>5</issue><fpage>1256</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">11316667</pub-id></citation></ref><ref id="B34"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hogg</surname><given-names>JC</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Utokaparch</surname><given-names>S</given-names></name><etal/></person-group><article-title>The nature of small-airway obstruction in chronic obstructive pulmonary disease</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2004</year><volume>350</volume><issue>26</issue><fpage>2645</fpage><lpage>2653</lpage><pub-id pub-id-type="pmid">15215480</pub-id></citation></ref><ref id="B35"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parr</surname><given-names>DG</given-names></name><name><surname>White</surname><given-names>AJ</given-names></name><name><surname>Bayley</surname><given-names>DL</given-names></name><name><surname>Guest</surname><given-names>PJ</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study</article-title><source><italic>Respiratory Research</italic></source><year>2006</year><volume>7</volume><fpage>136</fpage><pub-id pub-id-type="pmid">17112387</pub-id></citation></ref><ref id="B36"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sauleda</surname><given-names>J</given-names></name><name><surname>Garc&#x000ed;a-Palmer</surname><given-names>FJ</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>G</given-names></name><name><surname>Palou</surname><given-names>A</given-names></name><name><surname>Agust&#x000ed;</surname><given-names>AGN</given-names></name></person-group><article-title>The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis</article-title><source><italic>American Journal of Respiratory and Critical Care Medicine</italic></source><year>2000</year><volume>161</volume><issue>1</issue><fpage>32</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">10619794</pub-id></citation></ref><ref id="B37"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>SA</given-names></name><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Stringer</surname><given-names>JR</given-names></name><name><surname>Knox</surname><given-names>AJ</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>Britton</surname><given-names>JR</given-names></name></person-group><article-title>The relation between peripheral blood leukocyte counts and respiratory symptoms, atopy, lung function, and airway responsiveness in adults</article-title><source><italic>Chest</italic></source><year>2001</year><volume>119</volume><issue>1</issue><fpage>105</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">11157591</pub-id></citation></ref><ref id="B38"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burnett</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>SL</given-names></name><name><surname>Chamba</surname><given-names>A</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis</article-title><source><italic>The Lancet</italic></source><year>1987</year><volume>330</volume><issue>8567</issue><fpage>1043</fpage><lpage>1046</lpage></citation></ref><ref id="B39"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noguera</surname><given-names>A</given-names></name><name><surname>Batle</surname><given-names>S</given-names></name><name><surname>Miralles</surname><given-names>C</given-names></name><etal/></person-group><article-title>Enhanced neutrophil response in chronic obstructive pulmonary disease</article-title><source><italic>Thorax</italic></source><year>2001</year><volume>56</volume><issue>6</issue><fpage>432</fpage><lpage>437</lpage><pub-id pub-id-type="pmid">11359957</pub-id></citation></ref><ref id="B40"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noguera</surname><given-names>A</given-names></name><name><surname>Busquets</surname><given-names>X</given-names></name><name><surname>Sauleda</surname><given-names>J</given-names></name><name><surname>Villaverde</surname><given-names>JM</given-names></name><name><surname>MacNee</surname><given-names>W</given-names></name><name><surname>Agust&#x000ed;</surname><given-names>AGN</given-names></name></person-group><article-title>Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease</article-title><source><italic>American Journal of Respiratory and Critical Care Medicine</italic></source><year>1998</year><volume>158</volume><issue>5, part 1</issue><fpage>1664</fpage><lpage>1668</lpage><pub-id pub-id-type="pmid">9817722</pub-id></citation></ref><ref id="B41"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'byrne</surname><given-names>PM</given-names></name><name><surname>Postma</surname><given-names>DS</given-names></name></person-group><article-title>The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease. Asthma Research Group</article-title><source><italic>American Journal of Respiratory and Critical Care Medicine</italic></source><year>1999</year><volume>159</volume><issue>5, part 2</issue><fpage>S41</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">10228145</pub-id></citation></ref><ref id="B42"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phua</surname><given-names>J</given-names></name><name><surname>Koay</surname><given-names>ESC</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><article-title>Soluble triggering receptor expressed on myeloid cells-1 in acute respiratory infections</article-title><source><italic>European Respiratory Journal</italic></source><year>2006</year><volume>28</volume><issue>4</issue><fpage>695</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">16837506</pub-id></citation></ref><ref id="B43"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>Massin</surname><given-names>F</given-names></name></person-group><article-title>Soluble form of the triggering receptor expressed on myeloid cells 1: an anti-inflammatory mediator?</article-title><source><italic>Intensive Care Medicine</italic></source><year>2006</year><volume>32</volume><issue>2</issue><fpage>185</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">16450101</pub-id></citation></ref><ref id="B45"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Manfreda</surname><given-names>J</given-names></name><name><surname>Warren</surname><given-names>CP</given-names></name><name><surname>Hershfield</surname><given-names>ES</given-names></name><name><surname>Harding</surname><given-names>GK</given-names></name><name><surname>Nelson</surname><given-names>NA</given-names></name></person-group><article-title>Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease</article-title><source><italic>Annals of Internal Medicine</italic></source><year>1987</year><volume>106</volume><issue>2</issue><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">3492164</pub-id></citation></ref><ref id="B46"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hurst</surname><given-names>JR</given-names></name><name><surname>Perera</surname><given-names>WR</given-names></name><name><surname>Wilkinson</surname><given-names>TMA</given-names></name><name><surname>Donaldson</surname><given-names>GC</given-names></name><name><surname>Wedzicha</surname><given-names>JA</given-names></name></person-group><article-title>Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease</article-title><source><italic>American Journal of Respiratory and Critical Care Medicine</italic></source><year>2006</year><volume>173</volume><issue>1</issue><fpage>71</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">16179639</pub-id></citation></ref><ref id="B47"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sin</surname><given-names>DD</given-names></name><name><surname>Paul Man</surname><given-names>SF</given-names></name></person-group><article-title>Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease</article-title><source><italic>Circulation</italic></source><year>2003</year><volume>107</volume><issue>11</issue><fpage>1514</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">12654609</pub-id></citation></ref><ref id="B48"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Redd</surname><given-names>SC</given-names></name></person-group><article-title>Obstructive and restrictive lung disease and markers of inflammation: data from the third national health and nutrition examination</article-title><source><italic>The American Journal of Medicine</italic></source><year>2003</year><volume>114</volume><issue>9</issue><fpage>758</fpage><lpage>762</lpage><pub-id pub-id-type="pmid">12829203</pub-id></citation></ref><ref id="B49"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broekhuizen</surname><given-names>R</given-names></name><name><surname>Wouters</surname><given-names>EFM</given-names></name><name><surname>Creutzberg</surname><given-names>EC</given-names></name><name><surname>Schols</surname><given-names>AMWJ</given-names></name></person-group><article-title>Raised CRP levels mark metabolic and functional impairment in advanced COPD</article-title><source><italic>Thorax</italic></source><year>2006</year><volume>61</volume><issue>1</issue><fpage>17</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">16055618</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>ELISA for sTREM-1. (a) Titration of recombinant human TREM-1::IgG1 either in the absence (filled symbols) or presence of normal human serum (open symbols). (b) Serial dilution of serum from a septic patient. The <inline-formula><mml:math id="M48"><mml:mrow><mml:msup><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> values are the correlation coefficients of the depicted data.</p></caption><graphic xlink:href="CDI2007-52040.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Concentration of sTREM-1 in serum of healthy controls (controls) and patients with COPD.</p></caption><graphic xlink:href="CDI2007-52040.002"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Relationship between sTREM-1 serum levels and absolute FEV<sub>1</sub>(panel A), FEV<sub>1</sub>% predicted (panel B), residual volume (RV) % predicted (panel C), and diffusion capacity (DLCO) % predicted (panel D). Control subjects are represented by open circles, patients with COPD by closed circles.</p></caption><graphic xlink:href="CDI2007-52040.003"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Patients&#x02019; characteristics ( ND not done).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Control</th><th align="center" rowspan="1" colspan="1">COPD</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex (f/m)</td><td align="center" rowspan="1" colspan="1">4/6</td><td align="center" rowspan="1" colspan="1">5/7</td></tr><tr><td rowspan="1" colspan="1">Age (y)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M49"><mml:mrow><mml:mn>51</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>14</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M50"><mml:mrow><mml:mn>56</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M51"><mml:mrow><mml:mn>171</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>9</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M52"><mml:mrow><mml:mn>169</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">BMI (<inline-formula><mml:math id="M53"><mml:mrow><mml:mtext>kg</mml:mtext><mml:mo>/</mml:mo><mml:msup><mml:mrow><mml:mtext>m</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M54"><mml:mrow><mml:mn>26.9</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>6.1</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M55"><mml:mrow><mml:mn>23.3</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>4.5</mml:mn></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">Pack years of smoking</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M56"><mml:mrow><mml:mn>30</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub> (L)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M57"><mml:mrow><mml:mn>3.52</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>0.97</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M58"><mml:mrow><mml:mn>1.51</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mrow><mml:mn>0.68</mml:mn></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub> (%predicted)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M59"><mml:mrow><mml:mn>103</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>13</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M60"><mml:mrow><mml:mn>51</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mrow><mml:mn>20</mml:mn></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub>/FVC (%)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M61"><mml:mrow><mml:mn>73</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M62"><mml:mrow><mml:mn>52</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1"><inline-formula><mml:math id="M63"><mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:mrow></mml:math></inline-formula>FEV<sub>1</sub> Salbutamol (%)</td><td align="center" rowspan="1" colspan="1">N.D.</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M64"><mml:mrow><mml:mn>3.8</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>1.6</mml:mn></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">RV (%predicted)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M65"><mml:mrow><mml:mn>95</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>49</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M66"><mml:mrow><mml:mn>165</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mrow><mml:mn>63</mml:mn></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">ITGV (L)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M67"><mml:mrow><mml:mn>3.57</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>1.6</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M68"><mml:mrow><mml:mn>4.32</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mrow><mml:mn>1.4</mml:mn></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">DL<sub>CO</sub> (%predicted)</td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M69"><mml:mrow><mml:mn>94</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:mn>6</mml:mn></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1"><inline-formula><mml:math id="M70"><mml:mrow><mml:mn>61</mml:mn><mml:mo>&#x000b1;</mml:mo><mml:msup><mml:mrow><mml:mn>12</mml:mn></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td></tr><tr><td rowspan="1" colspan="1">sTREM-1 (ng/mL)</td><td align="center" rowspan="1" colspan="1">0.25 (0&#x02013;5.9) </td><td align="center" rowspan="1" colspan="1">11.68 (6.2&#x02013;41.9<inline-formula><mml:math id="M71"><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula></td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>* For abbreviations, see text. Mean values <inline-formula><mml:math id="M72"><mml:mrow><mml:mo>&#x000b1;</mml:mo></mml:mrow></mml:math></inline-formula> SD are given. For sTREM-1 median and range are given <inline-formula><mml:math id="M73"><mml:mrow><mml:mmultiscripts><mml:mrow><mml:mi>P</mml:mi><mml:mo>&#x0003c;</mml:mo><mml:mn>.05</mml:mn></mml:mrow><mml:mprescripts/><mml:none/><mml:mrow><mml:mo>*</mml:mo></mml:mrow></mml:mmultiscripts></mml:mrow></mml:math></inline-formula> regarding the comparison between groups.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 